letermovir: Clinical Trials

8 trials of letermovir, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 2 not yet recruiting, 2 recruiting, 2 unknown. 8 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 48Completed 2, Not yet recruiting 2, Recruiting 2, Unknown 2

Follow letermovir: new trials by email Literature Review of letermovir trials Research Report on letermovir

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Letermovir for R+ Study
Letermovir - Kidney Transplant, Liver Transplant
Phase 4Not yet recruitingUniversity of Wisconsin, Madison1462026-11-012026-11-19
Letermovir vs Valganciclovir in CMV R+ Kidney Transplant
Letermovir, Valganciclovir CMV Prophylaxis - CMV Infection, CMV
Phase 4Not yet recruitingElisabeth Kincaide3002026-05-012026-05-08
Combination Letermovir and Standard of Care Antiviral for Enhanced Antiviral Response in Cytomegalovirus Infection in Lung Transplant Recipients
Letermovir, Placebo, Valganciclovir/Ganciclovir - CMV, Lung Transplant Recipient
Phase 4RecruitingUniversity Health Network, Toronto402025-12-242026-02-17
Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Disease in Chinese Kidney Transplant Recipients
Letermovir, Valganciclovir - Kidney Transplant
Phase 4RecruitingFirst Affiliated Hospital Xi'an Jiaotong University2902025-05-132025-12-05
Secondary Prophylaxis of CMV Infection Using Letermovir After HID-HSCT
Letermovir for secondary prophylaxis - To Evaluate the Efficacy and Safety of Secondary Prophylaxis of CMV Reactivation
Phase 4UnknownInstitute of Hematology & Blood Diseases Hospital, China312023-07-012023-06-22
Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After R+HID-HSCT
Letermovir - The Incidence of Peripheral Blood CMV Activation and Confirmed Clinically Significant CMV Infection Within 24 Weeks After Transplantation
Phase 4UnknownInstitute of Hematology & Blood Diseases Hospital, China212023-07-012023-06-22
Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
Letermovir - Cytomegalovirus Infections, Infection in Solid Organ Transplant Recipients
Phase 4CompletedTufts Medical Center212023-02-022026-10-26
Letermovir Use in Heart Transplant Recipients
Letermovir - Cytomegalovirus Disease, Cytomegalovirus Infections
Phase 4CompletedTufts Medical Center322022-01-052025-07-29

Conditions studied

Cytomegalovirus Infections (4)  ·  Neutropenia (3)

Sponsors

Institute of Hematology & Blood Diseases Hospital, China (2)  ·  Tufts Medical Center (2)  ·  Elisabeth Kincaide (1)  ·  First Affiliated Hospital Xi'an Jiaotong University (1)  ·  University Health Network, Toronto (1)  ·  University of Wisconsin, Madison (1)

Countries

United States (4)  ·  Canada (1)  ·  China (1)

Top investigators

David Al-Adra, MD (1)  ·  Jennifer K Chow, MD, MS (1)